The Claim
Following discontinuation of tirzepatide, fat regain occurs preferentially in subcutaneous adipose depots (34%) compared to visceral adipose depots (7.5%), and the android-to-gynoid fat ratio decreases, indicating a shift toward a fat distribution pattern with lower metabolic risk.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
After stopping tirzepatide, fat that returns goes mostly under the skin rather than around internal organs, and the pattern of fat storage becomes less associated with metabolic disease.
See the scientific wording
After tirzepatide discontinuation, regained fat accumulates preferentially in subcutaneous depots (34%) rather than visceral depots (7.5%), and the android-to-gynoid fat ratio decreases, suggesting a shift toward a less metabolically harmful fat distribution.
When fat returns after stopping the drug, the body stores it mostly under the skin instead of around the organs because fat cells around the organs become less able to release stored fat, making them less likely to take up new fat, while fat cells under the skin keep their ability to store fat efficiently.
What the research says
1 studyStudy: 1676-P: Changes in Body Composition During and After Weight Loss with Tirzepatide
When people stopped taking tirzepatide and gained weight back, most of the fat came back under the skin—not around the organs—and the body stored it in a way that’s less risky for health.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.